RSS-Feed abonnieren
DOI: 10.1055/s-0042-1753494
Preliminary Report from a Randomized Controlled Trial Comparing Two Bovine Pericardial Valves
![](https://www.thieme-connect.de/media/thoracic/202308/lookinside/thumbnails/10-1055-s-0042-1753494_226507oc-1.jpg)
Abstract
Background A randomized controlled trial was designed to compare 1-year hemodynamic profiles and clinical outcomes after bioprosthetic aortic valve replacement (AVR) using a recently introduced (study group) and world-widely used (control group) bovine pericardial bioprostheses. This study evaluated early postoperative outcomes as a preliminary analysis.
Methods The primary end point of the trial was the mean pressure gradient across the aortic valve (AVMPG) at 1 year after surgery. Patients were screened to enroll 70 patients in each group based on a noninferiority design. Early postoperative hemodynamic and clinical outcomes were compared between the two groups.
Results There were no differences in baseline characteristics, including sex and body surface area (1.64 ± 0.18 vs. 1.65 ± 0.15 m2) between the two groups. The AVMPG on early postoperative echocardiography was 15.2 ± 4.6 mm Hg and 16.5 ± 6.2 mm Hg in the study and control groups, respectively (p = 0.177). Although AVMPG of the 19 mm prostheses was lower in the study group than in the control group (17.0 ± 6.3 mm Hg vs. 22.8 ± 6.6 mm Hg, p = 0.039), there were no significant differences in the effective orifice area in all patients (1.57 ± 0.41 cm2 vs. 1.53 ± 0.34 cm2, p = 0.568), and each valve size. The effective orifice area index was also similar between the two groups in overall (p = 0.352), and in each valve size. There were no significant differences in clinical outcomes including operative mortality and postoperative complications between the two groups.
Conclusion Early postoperative hemodynamic and clinical results after AVR using a recently introduced bovine pericardial valve were comparable with those using the control valve (NCT03796442)
* These authors contributed equally to the study.
Publikationsverlauf
Eingereicht: 28. Januar 2022
Angenommen: 08. Juni 2022
Artikel online veröffentlicht:
02. August 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Otto CM, Nishimura RA, Bonow RO. et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143 (05) e72-e227
- 2 Baumgartner H, Falk V, Bax JJ. et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38 (36) 2739-2791
- 3 Klautz RJM, Kappetein AP, Lange R. et al; PERIGON Investigators. Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis. Eur J Cardiothorac Surg 2017; 52 (03) 425-431
- 4 Sabik III JF, Rao V, Lange R. et al; PERIGON Investigators. One-year outcomes associated with a novel stented bovine pericardial aortic bioprosthesis. J Thorac Cardiovasc Surg 2018; 156 (04) 1368-1377.e5
- 5 Dagenais F, Moront MG, Brown WM. et al. Safety, efficacy, and hemodynamic performance of a stented bovine pericardial aortic valve bioprosthesis: two-year analysis. J Thorac Cardiovasc Surg 2020; 160 (02) 371-381.e4
- 6 Klautz RJM, Vriesendorp MD, Dagenais F. et al. Antithrombotic therapy and bleeding events after aortic valve replacement with a novel bioprosthesis. J Thorac Cardiovasc Surg 2019; 161: 66-75
- 7 Rennie D. How to report randomized controlled trials. The CONSORT statement. JAMA 1996; 276 (08) 649
- 8 Lancellotti P, Pibarot P, Chambers J. et al. Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016; 17 (06) 589-590
- 9 Akins CW, Miller DC, Turina MI. et al; Councils of the American Association for Thoracic Surgery, Society of Thoracic Surgeons, European Assoication for Cardio-Thoracic Surgery, Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity. Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg 2008; 135 (04) 732-738
- 10 Fiegl K, Deutsch MA, Rondak IC, Lange R, Guenzinger R. Matched comparison of two different biological prostheses for complete supra-annular aortic valve replacement. Thorac Cardiovasc Surg 2015; 63 (06) 459-466
- 11 Wendt D, Thielmann M, Plicht B. et al. The new St Jude Trifecta versus Carpentier-Edwards Perimount Magna and Magna Ease aortic bioprosthesis: is there a hemodynamic superiority?. J Thorac Cardiovasc Surg 2014; 147 (05) 1553-1560
- 12 Wyss TR, Bigler M, Stalder M. et al. Absence of prosthesis-patient mismatch with the new generation of Edwards stented aortic bioprosthesis. Interact Cardiovasc Thorac Surg 2010; 10 (06) 884-887 , discussion 887–888
- 13 Baumgartner H, Hung J, Bermejo J. et al; EAE/ASE. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr 2009; 10 (01) 1-25
- 14 Bonow RO, Carabello BA, Kanu C. et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2006; 114 (05) e84-e231
- 15 Dunning J, Gao H, Chambers J. et al. Aortic valve surgery: marked increases in volume and significant decreases in mechanical valve use—an analysis of 41,227 patients over 5 years from the Society for Cardiothoracic Surgery in Great Britain and Ireland National database. J Thorac Cardiovasc Surg 2011; 142 (04) 776-782.e3
- 16 Dalmau MJ, González-Santos JM, Blázquez JA. et al. Hemodynamic performance of the Medtronic Mosaic and Perimount Magna aortic bioprostheses: five-year results of a prospectively randomized study. Eur J Cardiothorac Surg 2011; 39 (06) 844-852 , discussion 852
- 17 Ruzicka DJ, Hettich I, Hutter A. et al. The complete supraannular concept: in vivo hemodynamics of bovine and porcine aortic bioprostheses. Circulation 2009; 120 (Suppl. 11) S139-S145
- 18 Tadokoro N, Fukushima S, Shimahara Y. et al. Comparison of safety and haemodynamic performance between the Avalus™ stented aortic valve bioprosthesis and Magna™ valve in Japanese patients. Gen Thorac Cardiovasc Surg 2021; 69 (07) 1060-1069
- 19 Mayr B, Burri M, Vitanova K. et al. Serial echocardiographic evaluation of the Perimount Magna Ease prosthesis. J Thorac Dis 2021; 13 (07) 4104-4113
- 20 Lee H, Hwang HY, Sohn SH. et al. Hemodynamic performance of pericardial bioprostheses in the aortic position. Korean J Thorac Cardiovasc Surg 2020; 53 (05) 285-290
- 21 Bleiziffer S, Eichinger WB, Hettich I. et al. Prediction of valve prosthesis-patient mismatch prior to aortic valve replacement: which is the best method?. Heart 2007; 93 (05) 615-620
- 22 Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis-patient mismatch in the aortic valve position and its prevention. J Am Coll Cardiol 2000; 36 (04) 1131-1141